Ziopharm’s Palifosfamide Fails In First-Line STS
Edison | Mar 27, 2013 08:28AM ET
We view the failure of Ziopharm’s (ZIOP) palifosfamide in metastatic soft tissue sarcoma (STS) as incrementally positive for CytRx’s aldoxorubicin. It eliminates a potential competitor in the first-line setting and critically, confirms doxorubicin as the ‘gold standard’ comparator for its ongoing Phase IIb study in front-line STS. Our CytRx valuation of $120m ($4.0/share) remains unchanged following the palifosfamide news as we currently value aldoxorubucin in second-line STS only. However, this could change if front-line Phase IIb data are positive in H213.
Ziopharm’s palifosfamide fails in first-line STS…
Ziopharm has terminated the development of palifosfamide in metastatic STS following the failure of its Phase III PICASSO-3 study. Results showed that front-line treatment with palifosfamide plus doxorubicin failed to significantly improve progression free survival (PFS) vs doxorubicin alone (6.2 vs 5.2mths). Patients on combination therapy also showed a doubling in the rate of febrile neutropenia.
…Eliminating potential competitor to aldoxorubicin
There are now two products in mid-to-late stage development for first-line STS – Threshold’s TH-302 (Phase III) and CytRx’s aldoxorubicin (Phase IIb). Further clarity on the competitive landscape in first-line STS could emerge mid-2013, when Threshold conducts an interim PFS futility analysis for TH-302. Assuming TH-302 is not futile, the next datapoint will be an interim overall survival (OS) analysis around end-2013. For aldoxorubicin, headline PFS data from the head-to-head study vs doxorubicin is expected in H213. Critically, the failure of palifosfamide not only eliminates a first-line competitor, but also confirms doxorubicin as the ‘gold standard’ comparator drug.
Aldoxorubicin second-line Phase III to start Q313
We view 2013 as a transformative year for CytRx as it delivers important clinical data, regulatory milestones and Phase III starts for its oncology pipeline. The major value inflection points, in our view are: (1) FDA agreement (SPA) in Q213 for the aldoxorubicin Phase III trial in second-line STS, (2) aldoxorubicin Phase IIb data in first-line STS, and (3) tamibarotene Phase II data in advanced lung cancer in Q413.
Valuation: Risk-adjusted NPV of $120m
We value CytRx at $120m, or $4.00/share, based on a risk-adjusted NPV analysis. The failure of palisfosfamide does not impact our rNPV at present as we currently attribute value to aldoxorubicin in second-line STS only. However, this could change if headline Phase IIb data in front-line STS is positive in late Q313.
Get The News You Want
To Read the Entire Report Please Click on the pdf File Below.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.